Immiunologie and Pathology, Universitéde Brest, Université Européenne de Bretagne, Brest, France.
Adv Exp Med Biol. 2011;711:50-60. doi: 10.1007/978-1-4419-8216-2_5.
Although not exclusive, mounting evidence supports the fact that DNA methylation at CpG dinucleotides controls B-cell development and the progressive eliminati or inactivation of autoreactive B cell. Indeed, the expression of different B ce specific factors, including Pax5, rearrangement of the B-cell receptor (BCR) and cytokine production are tightly controlled by DNA methylation. Among normal B cells, the autoreactive CD5+ B cell sub-population presents a reduced capacity to methylate its DNA that leads to the expression of normally repressed genes, such as the human endogenous retrovirus (HERV). In systemic lupus erythematosus (SLE) patients, the archetype ofautoimmune disease, autoreactive B cells are characterized by their inability to induce DNA methylation that prolongs their survival. Finally, treating B cells with demethylating drugs increased their autoreactivity. Altogether this suggests that a deeper comprehension ofDNA methylation in B cells may offer opportunities to develop new therapeutics to control autoreactive B cells.
虽然并非排他性的,但越来越多的证据支持这样一个事实,即 CpG 二核苷酸的 DNA 甲基化控制 B 细胞的发育和自身反应性 B 细胞的逐渐消除或失活。事实上,不同 B 细胞特异性因子的表达,包括 Pax5、B 细胞受体 (BCR) 的重排和细胞因子的产生,都受到 DNA 甲基化的严格控制。在正常 B 细胞中,自身反应性 CD5+B 细胞亚群的 DNA 甲基化能力降低,导致正常受抑制基因的表达,如人类内源性逆转录病毒 (HERV)。在系统性红斑狼疮 (SLE) 患者中,这种自身免疫性疾病的典型代表,自身反应性 B 细胞的特征是它们不能诱导 DNA 甲基化,从而延长其存活时间。最后,用去甲基化药物治疗 B 细胞增加了它们的自身反应性。总之,这表明深入了解 B 细胞中的 DNA 甲基化可能为开发新的治疗方法来控制自身反应性 B 细胞提供机会。